Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 3 (2006), Issue 10 (October)

1. Dosimetric comparison of four target alignment methods for prostate cancer radiotherapy.
   Int J Radiat Oncol Biol Phys, 66(3): 883-91. [Abstract] [Full-text]
2. Daily variations in delivered doses in patients treated with radiotherapy for localized prostate cancer.
   Int J Radiat Oncol Biol Phys, 66(3): 876-82. [Abstract] [Full-text]
3. Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compared with three-dimensional conformal radiation therapy in clinically localized prostate cancer.
   Int J Radiat Oncol Biol Phys, 66(3): 654-62. [Abstract] [Full-text]
4. Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial.
   Int J Radiat Oncol Biol Phys, 66(3): 647-53. [Abstract] [Full-text]
5. Relationship between delay in radiotherapy and biochemical control in prostate cancer.
   Int J Radiat Oncol Biol Phys, 66(3): 663-8. [Abstract] [Full-text]
6. Pitch, roll, and yaw variations in patient positioning.
   Int J Radiat Oncol Biol Phys, 66(3): 949-55. [Abstract] [Full-text]
7. Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone: a multiinstitutional pooled analysis.
   Cancer, 107(7): 1496-502. [Abstract] [Full-text]
8. Second malignancies after prostate brachytherapy: incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up.
   Int J Radiat Oncol Biol Phys, 66(3): 669-73. [Abstract] [Full-text]
9. Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival.
   Int J Cancer, 119(10): 2428-34. [Abstract] [Full-text]
10. Gleason score, age and screening: modeling dedifferentiation in prostate cancer.
    Int J Cancer, 119(10): 2366-71. [Abstract] [Full-text]
11. Improving the outcome of patients with castration-resistant prostate cancer through rational drug development.
    Br J Cancer, 95(7): 767-74. [Abstract] [Full-text]
12. Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy.
    J Natl Cancer Inst, 98(19): 1420-4. [Abstract] [Full-text]
13. Therapy Insight: parenteral estrogen treatment for prostate cancer--a new dawn for an old therapy.
    Nat Clin Pract Oncol, 3(10): 552-63. [Abstract] [Full-text]
14. S100A4 accelerates tumorigenesis and invasion of human prostate cancer through the transcriptional regulation of matrix metalloproteinase 9.
    Proc Natl Acad Sci U S A, 103(40): 14825-30. [Abstract] [Full-text]
15. A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy.
    BJU Int, 98(4): 763-9. [Abstract] [Full-text]
16. The role of alpha-blockers in the management of lower urinary tract symptoms in prostate cancer patients treated with radiation therapy.
    Am J Clin Oncol, 29(5): 517-23. [Abstract] [Full-text]
17. Is there a detrimental effect of waiting for radiotherapy for patients with localized prostate cancer?
    Am J Clin Oncol, 29(5): 463-7. [Abstract] [Full-text]
18. A prostate specific antigen (PSA) bounce greater than 1.4 ng/mL Is clinically significant after external beam radiotherapy for prostate cancer.
    Am J Clin Oncol, 29(5): 458-62. [Abstract] [Full-text]
19. Matched-pair analysis of prostate cancer patients with a high risk of positive pelvic lymph nodes treated with and without pelvic RT and high-dose radiation using high dose rate brachytherapy.
    Am J Clin Oncol, 29(5): 451-7. [Abstract] [Full-text]
20. Radiation rescue for biochemical failure after surgery for prostate cancer: predictive parameters and an assessment of contemporary predictive models.
    Am J Clin Oncol, 29(5): 446-50. [Abstract] [Full-text]
21. Modulation of ceramide metabolism enhances viral protein apoptin's cytotoxicity in prostate cancer.
    Mol Ther, 14(5): 637-46. [Abstract] [Full-text]
22. High dose calcitriol may reduce thrombosis in cancer patients.
    Br J Haematol, 135(3): 392-4. [Abstract] [Full-text]
23. Neoplastic lumbosacral radiculoplexopathy in prostate cancer by direct perineural spread: an unusual entity.
    Muscle Nerve, 34(5): 659-65. [Abstract] [Full-text]
24. Inhibition of prostate cancer cell growth by human secreted PDZ domain-containing protein 2, a potential autocrine prostate tumor suppressor.
    Endocrinology, 147(11): 5023-33. [Abstract] [Full-text]
25. Valproic acid inhibits invasiveness in bladder cancer but not in prostate cancer cells.
    J Pharmacol Exp Ther, 319(2): 533-42. [Abstract] [Full-text]
26. Nuclear interaction of Smac/DIABLO with Survivin at G2/M arrest prompts docetaxel-induced apoptosis in DU145 prostate cancer cells.
    Biochem Biophys Res Commun, 350(4): 949-54. [Abstract] [Full-text]
27. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging.
    Radiology, 241(2): 449-58. [Abstract] [Full-text]
28. Evaluation of urokinase plasminogen activator and its receptor in different grades of human prostate cancer.
    Hum Pathol, 37(11): 1442-51. [Abstract] [Full-text]
29. Gene expression profiling in R-flurbiprofen-treated prostate cancer: R-Flurbiprofen regulates prostate stem cell antigen through activation of AKT kinase.
    Biochem Pharmacol, 72(10): 1257-67. [Abstract] [Full-text]
30. Combined in vivo effect of A12, a type 1 insulin-like growth factor receptor antibody, and docetaxel against prostate cancer tumors.
    Clin Cancer Res, 12(20): 6153-60. [Abstract] [Full-text]
31. Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy.
    Clin Cancer Res, 12(20): 6116-24. [Abstract] [Full-text]
32. Pharmacokinetics and toxicity of weekly docetaxel in older patients.
    Clin Cancer Res, 12(20): 6100-5. [Abstract] [Full-text]
33. Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis.
    Clin Cancer Res, 12(20): 6094-9. [Abstract] [Full-text]
34. Prognostic value of prostate secretory protein of 94 amino acids and its binding protein after radical prostatectomy.
    Clin Cancer Res, 12(20): 6018-22. [Abstract] [Full-text]
35. Glucocorticoids suppress tumor lymphangiogenesis of prostate cancer cells.
    Clin Cancer Res, 12(20): 6012-7. [Abstract] [Full-text]
36. Expression of stress response protein Grp78 is associated with the development of castration-resistant prostate cancer.
    Clin Cancer Res, 12(20): 5987-93. [Abstract] [Full-text]
37. Tissue evidence of the testosterone role on the abnormal growth and aging effects reversion in the gerbil (Meriones unguiculatus) prostate.
    Anat Rec A Discov Mol Cell Evol Biol, 288(11): 1190-200. [Abstract] [Full-text]
38. Induction of protective immunity to RM-1 prostate cancer cells with ALVAC-IL-2/IL-12/TNF-alpha combination therapy.
    Int J Cancer, 119(11): 2632-41. [Abstract] [Full-text]
39. Dose escalation to combat hypoxia in prostate cancer: a radiobiological study on clinical data.
    Br J Radiol, 79(947): 905-11. [Abstract] [Full-text]
40. Transperineal permanent seed implantation of "low-risk" prostate cancer: 5-year-experiences in 118 patients.
    Strahlenther Onkol, 182(11): 666-71. [Abstract] [Full-text]
41. Health-related quality of life after permanent interstitial brachytherapy for prostate cancer: correlation with postimplant CT scan parameters.
    Strahlenther Onkol, 182(11): 660-5. [Abstract] [Full-text]
42. The impact of IMRT and proton radiotherapy on secondary cancer incidence.
    Strahlenther Onkol, 182(11): 647-52. [Abstract] [Full-text]
43. Pentosan polysulfate (Elmiron): in vitro effects on prostate cancer cells regarding cell growth and vascular endothelial growth factor production.
    Am J Surg, 192(5): 640-3. [Abstract] [Full-text]
44. Metallothionein isoform II expression in hyperplastic, dysplastic and neoplastic prostatic lesions.
    J Clin Pathol, 59(11): 1171-4. [Abstract] [Full-text]
45. Hinokitiol, a metal chelator derived from natural plants, suppresses cell growth and disrupts androgen receptor signaling in prostate carcinoma cell lines.
    Biochem Biophys Res Commun, 351(1): 26-32. [Abstract] [Full-text]

© 2004-2008 Prostate Cancer Research Today. All Rights Reserved.